Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

Acquired Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura: a Collaborative Study Proposal of the Spanish Apheresis Group (GEA) in Collaboration With the Spanish Foundation of Hematology and Hemotherapy (FEHH)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05046717
• Other study ID #: INSPIRER
• Status: Recruiting
• Start date: October 13, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: November 2023
• Source: Fundación Española de Hematología y Hemoterapía
• Contact: Cristina Pascual, MD
• Phone: +34 91 586 8445
• Email: cpascuali[@]salud.madrid.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other TMA. Furthermore, monitoring of ADAMTS13 activity is useful to ensure biological remission (ADAMTS13 levels > 10%) as well as predicting relapses. Due to the high mortality rate of aTTP, treatment should be started as soon as the disease is suspected, sometimes even before confirmation with the ADAMTS13 test results. This situation may lead to misdiagnose some patients and leave them without the appropriate treatment. In conclusion, ADAMTS13 activity assay is crucial for an early diagnosis and optimal management of acute aTTP and any delay in ADAMTS13 results will have a negative impact on the diagnosis, treatment and prognosis of the patient. There are currently 2 techniques available for the ADAMTS13 activity determination, the fluorescence resonance energy transfer (FRET) and the Technozym chromogenic enzyme-linked immunosorbent assay (ELISA). Both are considered reference methods but they require considerable skill because they are highly manual and this increases the risk of error. Furthermore, these methods are time-consuming, not widely available and, in case of the ELISA method, it requires a new calibration at each run. The inter-laboratory variability is also a challenge and therefore a validation and/or interpretation method could be needed. Recently, a new and first fully automated HemosIL AcuStar ADAMTS13 Activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States) has been developed. HemosIL AcuStar ADAMTS13 Activity assay is a two steps chemiluminescent immunoassay (CLIA) with an analytical time of 33 minutes for the quantitative measurement of ADAMTS13 activity in human-citrated plasma on the ACL AcuStar analyser. The immunoassay uses the GST-VWF73 substrate in combination with magnetic particles for rapid separation and chemiluminescence technology detection. The ADAMTS13 present in the plasma sample cleavages the GST-VWF73 substrate and the detection of the generated fragments is based upon an isoluminol-labelled monoclonal antibody that specifically reacts with the cleaved peptide. The emitted light is proportional to the ADAMTS13 activity in the sample. This new ADAMTS13 assay method has been compared with the other two available techniques in two different studies. First, Favresse et al. published the results of the comparison between Technozym activity ELISA assay and the new HemosIL AcuStar chemiluminescent assay. On the other hand, Valsecchi et al. have recently published the results of validation of this new technique in comparison with ELISA and FRETS in 176 samples. Both studies conclude that the new chemiluminescent ADAMTS13 activity assay showed a good correlation and excellent clinical performance for the diagnosis of severe ADAMTS13 deficiency with the FRETS-VWF73 assay and a commercial ELISA when considering only ADAMTS13 activity values below 10% (the internationally accepted cut-off for a diagnosis of severe ADAMTS13 deficiency typical of aTTP). Finally, Stratmann et al. have just published another study comparing the HemosIL AcuStar chemiluminescent assay with two commercially available ADAMTS13 assay kits using 24 paired test samples derived from 10 consecutively recruited patients13 and their results corroborate the previously published data suggesting that the AcuStar assay could be a valuable and accurate tool for ADAMTS13 activity testing and aTTP diagnostic. In this context, a unique opportunity to validate this new technique is generated, both retrospectively with our already available data from frozen samples and also in the context of a large prospective study. This will be the first study worldwide testing HemosIL AcuStar method in real clinical practice aTTP population (Spanish and Portuguese aTTP populations) with the aim to standardize the diagnosis and follow-up methodology for the disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 30, 2025
• Est. primary completion date: October 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 99 Years

Eligibility

Inclusion Criteria:

• Patients with confirmed thrombotic microangiopathy (TMA) based on citrated blood

samples meeting both of the following criteria:

• Thrombocytopenia [drop in platelet count =50% or platelet count < 100x109/L and
• Microangiopathic haemolytic anaemia (elevation of lactate dehydrogenase (LDH) >2- fold or by presence or increase of schistocytes in peripheral blood smear)
• Patients that voluntarily sign informed consent. For subjects unable to provide consent, a fully recognized medical proxy may be used according to local laws.
• Patients between 0 to 99 years old at the time of screening. Exclusion Criteria: -

Related Conditions & MeSH terms

• Acquired Thrombotic Thrombocytopenic Purpura
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombotic Thrombocytopenic

Intervention

Device:
• ADAMTS13 Activity Assays
In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits: HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States) ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain) FRETS-VWF73 for ADAMTS13 Activity Assay Three kits will be used with all patients.

Locations

Country	Name	City	State
Portugal	Centro Hospitalar e Universitario de Coimbra	Coimbra
Spain	Complejo Hospitalario Universitario A Coruña	A Coruña
Spain	Hospital Clinic de Barcelona	Barcelona
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Gregorio Marañon	Madrid
Spain	Hospital La Fe de Valencia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Española de Hematología y Hemoterapía

Countries where clinical trial is conducted

Portugal,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Primary	Correlation of a new diagnostic test and standard test	Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL	At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients at diagnosis based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Concordance of classification of aTTP	To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Sensitivity and specificity of classification of aTTP	To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.	At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (10 days)
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (30 days)
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (60 days)
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (90 days)
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (180 days)
Secondary	Clinical characteristics	Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.	At follow up (365 days)